# i02 strong-solver screen: raw returns (2026-10-18)

Three fresh blind-solver contexts (claude-opus-5-5, effort max), each given only the workspace root,
the packet path runs/i02-screen-e2dd112e124dd805/solver-1 and the exact sentence. Gold: $249.4 million.
Returns kept verbatim in substance (harness indentation removed), numbered in order of arrival.

## Solve 1: $249.4 million (right), confidence high

answer: 249.4 (fiscal Q4, March 1 to May 31, 2026)

confidence: high

path:
1. Scope. Fiscal 2026 runs June 1, 2025 to May 31, 2026. D02 line 305 says "fiscal year ended May 31, 2026 ("fiscal 2026")". That gives four quarters: Q1 ending Aug 31, 2025, Q2 ending Nov 30, 2025, Q3 ending Feb 28, 2026, and Q4 ending May 31, 2026.
2. Q1 = $160.1M. In D02 (Q1 FY2027 10-Q), the equity statement's comparative column "For the three months ended August 31, 2025" shows "Repurchases of common shares(2)|(1.1)|(0.0)|(5.3)|(154.8)|…|(160.1)" (line 218). The cash flow line agrees: "Repurchases of common shares|—|(160.1)" (line 274). The text matches it too: "1.1 million shares … at a weighted average price of $145.59" (line 1269).
3. Q2 = $126.5M. D04 (Q2 FY2026 10-Q) shows, for the three months ended Nov 30, 2025, "Repurchases of common shares (2)|(1.0)|…|(126.5)" (line 220). The Item 2 table has "October 1, 2025 - October 31, 2025|1.0|122.54|126.5|$9.4" (line 1496). The six-month total is 286.6 (line 205), and 286.6 − 160.1 = 126.5.
4. Q3 = $75.0M. D06 (Q3 FY2026 10-Q), three months ended Feb 28, 2026, shows "Repurchases of common shares (2)|(0.8)|…|(75.0)" (line 220). The nine-month total is 361.6 (lines 205 and 316), and 361.6 − 286.6 = 75.0. In Item 2, the remaining authorization goes from $9.4 (Dec) to $950.0 (Jan, $50.0 bought) to $925.0 (Feb, $25.0 bought), ending with "Total for the period|0.8|$99.05|$75.0|$925.0" (lines 1525-1528).
5. Program facts. D02, D06 footnote (2): the $400.0M program "expired on January 16, 2026, at which time $9.4 million of unused repurchase authorization expired. On January 16, 2026, the Company's Board approved a program to repurchase up to an additional $1.0 billion … with no expiration date." No other program is disclosed through Aug 31, 2026 (D02 line 1400).
6. No purchases in fiscal 2027 Q1. D02 equity statement: "Repurchases of common shares (2)|—|…|—" (line 203). D02 Item 2: "June 1, 2026 - June 30, 2026|—|$—|$—|$675.6" (line 1404), and July, August and the period total are also $675.6. Since nothing was bought in June, $675.6M was left at May 31, 2026.
7. Q4 = 925.0 − 675.6 = $249.4M. As a check, 1,000 − 675.6 = 324.4 used under the new program, and 324.4 − 75.0 (Q3) = 249.4.
8. Rough sanity check: shares outstanding fell from 358.3 (D06 line 179) to 355.6 (D02 line 177). That is about 2.8M shares bought less about 0.1M issued under equity plans, at roughly $90 a share, which fits $249.4M. Additional paid-in capital also roughly fits: 1,965.4 + about 23 stock-based compensation − about 14 for repurchases ≈ 1,975.6.
9. Ranking: Q4 249.4 > Q1 160.1 > Q2 126.5 > Q3 75.0. The four quarters sum to 611.0.

minimal_documents: D02 + D06. Q1 comes from D02. Q3, the nine-month total and the $925.0 remaining come from D06. Q2 = 361.6 − 160.1 − 75.0 = 126.5. Q4 = 925.0 − 675.6. Alternative set: D02 + D04 + D05. D04 shows $9.4M left on the old program at Nov 30, 2025, and D02 says the same $9.4M expired unused, so all purchases after Nov 30, 2025 were under the new program, totalling 324.4. Q3 = 361.6 (D05 line 120) − 286.6 (D04) = 75.0, so Q4 = 324.4 − 75.0 = 249.4. D03 can stand in for D04 for the six-month $286.6M (line 126), but not for the $9.4M remaining. D01 has only the Q1 cash flow line (160.1) and can stand in for D02's Q1 figure, but not for the $675.6M.

readings:
- Counting only quarters whose repurchases are printed directly (Q1 to Q3), with no fourth-quarter derivation, the answer would be 160.1. That leaves out Q4, which the question covers and which can be worked out from the packet.
- If "dollar value" were taken to include any excise tax booked in Q4, the figure could differ. No fiscal 2026 excise tax is disclosed in the packet. For Q2 and Q3, the amounts in the equity statement, the Item 2 tables and the drop in remaining authorization are identical, which supports 249.4.

gaps:
- The packet has no fiscal 2026 10-K or Q4 release, so Q4 is derived from the "Approximate dollar value of shares that may yet be purchased" figures, not printed directly. The derivation assumes no repurchases outside a program and no new authorizations; nothing in the packet suggests either.
- All sources are plain text (method "text", no PDFs or layout files), so there were no extraction checks to make.
- Coverage: searched all six documents for repurchase, authorization, excise, subsequent-event and fiscal-2026 terms. Read the equity statements, cash flow statements and Item 2 sections of D02, D04 and D06, the shareholder-return sections of D01, D03 and D05, and the matching MD&A lines. Did not read the rest of the documents in full, and did not open the packet's question.txt.

contaminated: no

## Solve 2: $249.4 million (right), confidence high

answer: $249.4 million. This is the fourth quarter of fiscal 2026 (March 1 to May 31, 2026). No document states it directly; it is derived from the repurchase authorization balances.

confidence: high. The derivation assumes the authorization did not change between February 28 and May 31, 2026. No document discloses any change: no new program and no expiry, because the $1.0B program has "no expiration date".

path:
Fiscal 2026 runs June 1, 2025 to May 31, 2026. The packet has no FY2026 10-K or Q4 release, so I took Q1–Q3 from the 10-Qs and derived Q4.
1. Q1 FY2026 = $160.1M. D02 (Q1 FY2027 10-Q), equity statement "For the three months ended August 31, 2025", line 218: "Repurchases of common shares(2)|(1.1)|(0.0)|(5.3)|(154.8)|—|—|—|(160.1)". The cash flow 2025 column, line 274, shows the same (160.1). D02 line 1269: "repurchase 1.1 million shares ... at a weighted average price of $145.59 per share during the first quarter" (1.1 × 145.59 ≈ 160.1).
2. Q2 FY2026 = $126.5M. D04 (Q2 FY2026 10-Q), equity statement for the three months ended Nov 30, 2025, line 220: "(126.5)". D04 Item 2, line 1498: "Total for the period|1.0|$122.54|$126.5|$9.4". Cross-check: six-month total (286.6, D04 line 205 and D03 line 126) − 160.1 = 126.5.
3. Q3 FY2026 = $75.0M. D06 (Q3 FY2026 10-Q), three months ended Feb 28, 2026, line 220: "(75.0)". Cross-check: nine-month total 361.6 (D06 line 205, D05 line 120) − 286.6 = 75.0.
4. Q4 FY2026, derived from the amount still available under the program: D06 Item 2, lines 1527–1528: "February 1, 2026 - February 28, 2026|0.3|92.65|25.0|$925.0" and "Total for the period|0.8|$99.05|$75.0|$925.0". So $925.0M was available at Feb 28, 2026. D02 Item 2, lines 1404–1407: "June 1, 2026 - June 30, 2026|—|$—|$—|$675.6", with the same $675.6 in July, August and the period total. Nothing was bought in June, so $675.6M was available at May 31, 2026. D02 line 1400 mentions only the January 16, 2026 program of "an additional $1.0 billion ... with no expiration date". Q4 = 925.0 − 675.6 = 249.4.
5. Check that the dollar figures and the authorization balances track each other: the old $400M program lost exactly the reported quarterly amounts: 296.0 → 135.9 (Q1, 160.1) → 9.4 (Q2, 126.5). The $9.4M then expired unused on Jan 16, 2026 (D02 line 228, D06 line 230). The new program went 1,000.0 → 950.0 → 925.0 (Q3, 75.0).
6. Plausibility check: shares outstanding fell from 358.3M at Feb 28, 2026 (D06 line 209) to 355.6M at May 31, 2026 (D02 line 198), a drop of 2.7M. Q3's buyback was only 0.8M shares, so a larger Q4 buyback fits. This only supports the result; it does not prove it.
7. Comparison: Q1 160.1, Q2 126.5, Q3 75.0, Q4 249.4. The largest is Q4 at $249.4M.

The original docs/ text files confirm the decisive figures: Q3 10-Q lines 1616–1617 ($925.0) and Q1 FY2027 10-Q lines 1485–1488 ($675.6).

minimal_documents: D02 + D06. D02 supplies Q1 = 160.1 and the $675.6M balance at May 31, 2026. D06 supplies Q3 = 75.0, the nine-month total 361.6 (so Q2 = 361.6 − 75.0 − 160.1 = 126.5) and the $925.0M balance at Feb 28, 2026. Neither document alone is enough. D02 by itself gives only the combined usage of the new program from January 16 to May 31, 2026 (324.4). Alternative set: D02 + D04 + D05. D04 gives the $9.4M left on the old program at Nov 30, 2025 and Q2 = 126.5. D05 gives the nine-month 361.6, so Q3 = 75.0, all under the new program. The Feb 28 balance is then 1,000 − 75.0 = 925.0, and Q4 = 925.0 − 675.6 = 249.4. D01 and D03 are redundant; neither has an authorization table.

readings:
- Counting only quarters with a reported repurchase figure (Q1–Q3) gives $160.1M (Q1). This is weaker, because Q4 is part of the fiscal year asked about and can be derived from the packet.
- Treating the six-month ($286.6M) or nine-month ($361.6M) cumulative totals as a single quarter would be wrong.
- If a Q4 repurchase figure that includes excise tax were the intended measure, it is not in the packet. The quarters that are reported carry no excise-tax label, and their amounts equal the drop in authorization.

gaps:
- There is no FY2026 10-K or Q4 FY2026 release in the packet, so Q4 is derived, not stated.
- Q4 depends on the "approximate" authorization balances and on no undisclosed authorization changes.
- Q4 net income is unavailable, so I could not reconcile the result against retained earnings.
- Coverage: the manifest method is "text" for all six documents, so there are no PDFs or layout files. Searched all six text files for repurchase, buyback, authorization, treasury, retire, fiscal 2026, fourth quarter and May 31, 2026. Read D01 in full, plus the equity statements, cash flow statements, MD&A financing sections and Part II Item 2 of D02, D04 and D06. D03 and D05 seen only through search hits. The rest of the 10-Q notes was not read end to end.

contaminated: no. The packet directory contains question.txt; I did not open it. No answer, reasoning or hint leaked.

## Solve 3: $249.4 million (right), confidence high

answer: $249.4 million. This is the fiscal Q4 2026 figure (March 1 – May 31, 2026). It is not printed anywhere in the packet. I worked it out from the remaining buyback authorization reported at the end of Q3 and in the fiscal Q1 2027 report.

confidence: high

path:
1. Definition: D05 line 18 says "the fiscal year ending May 31, 2026 ("fiscal 2026")". So the quarters are Jun–Aug 2025, Sep–Nov 2025, Dec 2025–Feb 2026 and Mar–May 2026.
2. Q1 FY2026 = $160.1M. D02 equity statement, three months ended Aug 31, 2025, line 218: "Repurchases of common shares(2)|(1.1)|(0.0)|(5.3)|(154.8)|—|—|—|(160.1)". D02 cash flow, line 274: "Repurchases of common shares|—|(160.1)". D02 line 1269: "repurchase 1.1 million shares ... at a weighted average price of $145.59 per share during the first quarter". Cross-check: D04 six-month total 286.6 − Q2 126.5 = 160.1.
3. Q2 FY2026 = $126.5M. D04 three months ended Nov 30, 2025, line 220: "(1.0)|(0.0)|(4.9)|(121.6)|—|—|—|(126.5)". D04 Part II, line 1496: "October 1, 2025 - October 31, 2025|1.0|122.54|126.5|$9.4". September and November were zero.
4. Q3 FY2026 = $75.0M. D06 three months ended Feb 28, 2026, line 220: "(0.8)|(0.0)|(3.7)|(71.3)|—|—|—|—|(75.0)". D06 nine-month total, line 205: (361.6). 361.6 − 286.6 = 75.0.
5. Remaining authorization at Feb 28, 2026 = $925.0M. D06 line 1521 says the old $400M program "expired on January 16, 2026, at which time $9.4 million of unused repurchase authorization expired", and the Board approved "an additional $1.0 billion ... with no expiration date". D06 lines 1526–1528: "January ... 0.5|102.59|50.0|$950.0", "February ... 0.3|92.65|25.0|$925.0", "Total for the period|0.8|$99.05|$75.0|$925.0".
6. Remaining authorization at May 31, 2026 = $675.6M. D02 lines 1404–1407: "June 1, 2026 - June 30, 2026|—|$—|$—|$675.6", and the same through August. No other program is mentioned in D02. D02 cash flow line 274 and equity line 203 show no repurchases in Q1 FY2027. Because nothing was bought in June, the May 31 balance is also $675.6M.
7. Q4 FY2026 = 925.0 − 675.6 = 249.4. Check: 1,000.0 − 675.6 = 324.4 used under the new program in total; 324.4 − 75.0 (Q3) = 249.4.
8. Consistency checks: shares outstanding fell from 358.3M at Feb 28, 2026 (D06 line 179) to 355.6M at May 31, 2026 (D02 line 177), a net drop of 2.7M. That fits about 2.7–2.8M shares bought at roughly $89–92, since February's average price was $92.65. Additional paid-in capital rose 1,965.4 → 1,975.6 (+10.2). That fits stock-based compensation of about $20–25M minus about $13M from buybacks. Fiscal-year total: 160.1 + 126.5 + 75.0 + 249.4 = 611.0.
9. Largest quarter: Q4 at 249.4, ahead of Q1 160.1, Q2 126.5 and Q3 75.0.
10. I checked the figures 925.0, 950.0 and 675.6 against the docs/ source files (D06 source lines 1615–1617; D02 source lines 1485–1488). They match. The sources are .txt files, so there were no PDF pages to inspect.

minimal_documents: D02 + D06 (Q1 FY2027 10-Q and Q3 FY2026 10-Q). These alone give all four quarters: Q1 160.1 from D02, Q3 75.0 from D06, Q2 = 361.6 − 160.1 − 75.0 = 126.5, and Q4 = 925.0 − 675.6 = 249.4. Alternative: D02 + D05 + D03 (or D04). Q3 = 361.6 − 286.6 = 75.0. D02's note that the leftover $9.4M "expired" unused shows all Q3 buying was under the new $1.0B program. So Q4 = (1,000.0 − 675.6) − 75.0 = 249.4. D02 cannot be replaced. D01 has no authorization balance, and without it the equity roll-forward lacks Q4 net income and dividends.

readings:
- If only quarters with a printed quarterly figure count (Q1–Q3), the answer is $160.1M (Q1 FY2026). The question covers all four quarters, though, and the packet supports deriving Q4.
- The derived Q4 figure is the purchase price of the shares, which is what draws down the authorization. Any 1% excise tax would not be included. A fiscal-year cash-flow total from the 10-K, if it included excise tax, could make Q4 slightly larger. The 10-K is not in the packet, and the FY2026 Q1–Q3 statements show no excise-tax amounts.
- Calendar-quarter reading: not natural for this question, and the March 2026 monthly split is not available anyway.

gaps:
- The packet has no fiscal 2026 10-K or Q4 release, so the Q4 figure, its share count and its average price are derived rather than printed.
- Unread or only searched: most notes in D02, D04 and D06; the body of D03 (searched only); the D01 tables after line 127; D04 MD&A. Ran a search for "repurchas" across all six text files and looked for buyback, authorization, excise and program terms in the key files.
- No extraction problems found.

contaminated: no. I did not read question.txt or any notes, and no answer or hint came with the task.
